{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraneoplastic+Syndromes&page=2",
    "query": {
      "condition": "Paraneoplastic Syndromes",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Paraneoplastic+Syndromes&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T18:13:51.849Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04833894",
      "title": "Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-10-26",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04833894"
    },
    {
      "nct_id": "NCT04524273",
      "title": "Myasthenia Gravis Inebilizumab Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "inebilizumab",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2020-10-15",
      "completion_date": "2029-06-07",
      "has_results": true,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 16,
      "location_summary": "Orange, California • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04524273"
    },
    {
      "nct_id": "NCT05403541",
      "title": "Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Batoclimab 680 mg SC weekly",
          "type": "DRUG"
        },
        {
          "name": "Batoclimab 340 mg SC weekly",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "Batoclimab 340 mg SC bi-weekly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2022-06-27",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Olive View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05403541"
    },
    {
      "nct_id": "NCT00716066",
      "title": "Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autoimmune Disease",
        "Neurologic Autoimmune Disease",
        "Autologous Transplant Autoimmune",
        "Multiple Sclerosis Transplant",
        "MS Stem Cell Transplant",
        "Multiple Sclerosis Stem Cell Transplant",
        "Stiff Person Syndrome",
        "HCT for Neurologic Autoimmune Disorders",
        "CIDP Transplant",
        "Myasthenia Gravis Transplant",
        "Autoimmune Nervous System Disorder",
        "Central Nervous System Vasculitis",
        "Cerebellar Degeneration",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Lambert Eaton Myasthenic Syndrome",
        "Myasthenia Gravis",
        "Neuromyelitis Optica",
        "Opsoclonus Myoclonus Syndrome",
        "Rasmussen Subacute Encephalitis"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Syngeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "71 Years",
        "sex": "ALL",
        "summary": "Up to 71 Years"
      },
      "enrollment_count": 53,
      "start_date": "2008-06",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Seattle, Washington",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716066"
    },
    {
      "nct_id": "NCT07304154",
      "title": "A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Myasthenia Gravis",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "KITE-363",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 52,
      "start_date": "2026-04-10",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • New York, New York • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07304154"
    },
    {
      "nct_id": "NCT04980495",
      "title": "An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis",
        "MG - Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Efgartigimod IV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2021-12-16",
      "completion_date": "2025-10-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 12,
      "location_summary": "Carlsbad, California • Orange, California • Boca Raton, Florida + 9 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980495"
    },
    {
      "nct_id": "NCT06298565",
      "title": "A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "efgartigimod",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2024-11-04",
      "completion_date": "2034-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 17,
      "location_summary": "San Francisco, California • Boca Raton, Florida • Jacksonville Beach, Florida + 12 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Jacksonville Beach",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06298565"
    },
    {
      "nct_id": "NCT00872950",
      "title": "3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Lambert-Eaton Myasthenic Syndrome",
        "Congenital Myasthenic Syndrome"
      ],
      "interventions": [
        {
          "name": "3,4-DIAMINOPYRIDINE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lahey Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-04-11",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 1,
      "location_summary": "Burlington, Massachusetts",
      "locations": [
        {
          "city": "Burlington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00872950"
    },
    {
      "nct_id": "NCT07039916",
      "title": "Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "IMVT-1402",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 231,
      "start_date": "2025-05-27",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 47,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07039916"
    },
    {
      "nct_id": "NCT06704269",
      "title": "Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "YTB323",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2025-04-22",
      "completion_date": "2029-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-07-23T18:13:51.849Z",
      "location_count": 4,
      "location_summary": "Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06704269"
    }
  ]
}